Max P Kristiansen - Concepedia

Author

Max P Kristiansen

Statens Serum Institut

Also Known As

M. Kristiansen, MAX KRISTIANSEN, Max Kristiansen, Max P Kristiansen, Max P. Kristiansen, Max Per Kristiansen

Publications

674

Citations

H-Index

Concepts

All Affiliations

Statens Serum Institut Imperial College London FIND Novo Nordisk Foundation University of Copenhagen

About

Max P Kristiansen is an author at Statens Serum Institut specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	426
2	Allergy	2	2	164
3	Natural Sciences	1	1	26
4	Biochemistry	1	1	26
5	Epidemiology	1	1	21

Max P Kristiansen

Publications

656

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang, The Lancet Infectious Diseases VaccinationMucosal VaccinationCaf01 LiposomesImmunologyAluminium Hydroxide	2019	190
Bordetella pertussis and Chronic Cough in Adults Max P Kristiansen, Torben Seefeldt, J. Degn, Clinical Infectious Diseases VaccinationB. Pertussis InfectionB. Pertussis ReservoirsAllergyBordetella Pertussis	1999	143
Improved ELISA for determination of anti‐diphtheria and/or anti‐tetanus antitoxin antibodies in sera Max P Kristiansen, Henrik Aggerbeck, Iver Heron Apmis	1997	89
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients Synne Jenum, Kristian Tonby, Corina S. Rueegg, Nature Communications	2021	64
Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus. Michael S. Deming, J. B. Roungou, Max P Kristiansen, PubMed	2002	39
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial Katrina M. Pollock, Álvaro H. Borges, Hannah M. Cheeseman, The Lancet Infectious Diseases VaccinationChlamydia Vaccine Cth522Mucosal VaccinationTrachoma Vaccine RegimensVaccine Development	2024	29
Evaluation of spectral libraries and sample preparation for DIA-LC-MS analysis of host cell proteins: A case study of a bacterially expressed recombinant biopharmaceutical protein Søren Heissel, Jakob Bunkenborg, Max P Kristiansen, Protein Expression and Purification Dia-lc-ms AnalysisBiochemistryBiomolecular ToolNatural SciencesMedicine	2018	26
Fall‐off in immunity following diphtheria revaccination ‐ an 8 year follow‐up study Ole Simonsen, Max P Kristiansen, Henrik Aggerbeck, Apmis ImmunologyDiphtheria AntitoxinImmunotherapyCross-protectionYear Follow‐up Study	1996	21
Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice Anja Weinreich Olsen, Ida Rosenkrands, Christina S. Jacobsen, Nature Communications	2024	20
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial Álvaro H. Borges, Marisa Russell, Dereck Tait, The Lancet Infectious Diseases	2025	18

Page 1